Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PMCB
stocks logo

PMCB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
--
--
-0.090
+50%
Estimates Revision
Stock Price
Go Up
up Image
+28.57%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for PharmaCyte Biotech Inc (PMCB.O) is -3.18, compared to its 5-year average forward P/E of -9.62. For a more detailed relative valuation and DCF analysis to assess PharmaCyte Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.62
Current PE
-3.18
Overvalued PE
5.79
Undervalued PE
-25.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PMCB News & Events

Events Timeline

(ET)
2025-11-25
09:23:02
PharmaCyte divests Femasys shares, anticipates cash reserves increasing to $20M
select
2025-09-02 (ET)
2025-09-02
09:26:32
PharmaCyte Biotech Boosts Investment in TNF Pharmaceuticals by $3 Million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-26Benzinga
Autodesk Shares Rise Approximately 6%; 20 Stocks Making Moves in Premarket Trading

  • Autodesk's Strong Performance: Autodesk Inc reported third-quarter results with adjusted EPS of $2.67 and revenue of $1.85 billion, both exceeding analyst expectations, leading to a 6.1% increase in share price during pre-market trading.

  • Other Notable Gainers: Mobile-Health Network Solutions surged 45.4%, Inno Holdings gained 29.5%, and KALA Bio increased by 24.1% in pre-market trading, driven by various positive developments and agreements.

  • Significant Losers: Nutanix Inc saw a 16.8% drop after disappointing financial results and lowered sales guidance, while Biomx Inc and Kaixin Holdings also experienced notable declines of 13.2% and 12.1%, respectively.

  • Market Overview: The pre-market trading session showed mixed results, with several companies like Urban Outfitters and Petco Health and Wellness reporting better-than-expected earnings, while others faced declines due to poor financial performance.

[object Object]
Preview
7.5
11-25Newsfilter
PharmaCyte Monetizes Femasys Stake, Boosts Cash to $20 Million
  • Enhanced Financial Strength: PharmaCyte successfully monetized its stake in Femasys, with cash and marketable securities expected to rise from $13.3 million to approximately $20 million, significantly improving the company's financial stability and investment capacity.
  • Effective Strategic Execution: CEO Josh Silverman stated that this monetization validates the company's strategic and disciplined capital allocation approach, with plans to continue pursuing value-accretive investment opportunities to enhance shareholder returns.
  • Market Performance Analysis: Despite the improved financial position, PharmaCyte's stock currently trades at $0.65 per share with approximately 6.8 million shares outstanding, indicating a cautious market sentiment regarding its long-term value.
  • Ongoing Investment Strategy: PharmaCyte intends to maintain strict operational management and capital deployment strategies to further enhance shareholder returns while seizing high-quality investment opportunities.
[object Object]
Preview
8.5
09-02Newsfilter
PharmaCyte Biotech, Inc. Expands Investment in TNF Pharmaceuticals Following New License for Innovative Light Speed Computing Platform for Cryptocurrency Use

  • PharmaCyte Biotech's Investment: PharmaCyte Biotech has increased its investment in TNF Pharmaceuticals by $3 million to support TNF's acquisition of a license from LightSolver, a company recognized for its innovative computing technology that significantly reduces energy consumption and enhances computational speed.

  • Future Prospects and Strategy: TNF Pharmaceuticals plans to rebrand and focus on applying LightSolver's technology to cryptocurrency mining and blockchain, while PharmaCyte remains financially strong with over $55 million in assets and is exploring further investment opportunities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PharmaCyte Biotech Inc (PMCB) stock price today?

The current price of PMCB is 1.21 USD — it has increased 54.17 % in the last trading day.

arrow icon

What is PharmaCyte Biotech Inc (PMCB)'s business?

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

arrow icon

What is the price predicton of PMCB Stock?

Wall Street analysts forecast PMCB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMCB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PharmaCyte Biotech Inc (PMCB)'s revenue for the last quarter?

PharmaCyte Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is PharmaCyte Biotech Inc (PMCB)'s earnings per share (EPS) for the last quarter?

PharmaCyte Biotech Inc. EPS for the last quarter amounts to -1.23 USD, decreased -164.74 % YoY.

arrow icon

What changes have occurred in the market's expectations for PharmaCyte Biotech Inc (PMCB)'s fundamentals?

The market is revising No Change the revenue expectations for PMCB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.57%.
arrow icon

How many employees does PharmaCyte Biotech Inc (PMCB). have?

PharmaCyte Biotech Inc (PMCB) has 2 emplpoyees as of December 05 2025.

arrow icon

What is PharmaCyte Biotech Inc (PMCB) market cap?

Today PMCB has the market capitalization of 8.26M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free